Intracellular catabolism of an antibody drug conjugate with a noncleavable linker

Drug Metabolism and Disposition

Volumn 43, Issue 9, 2015, Pages 1341-1344

  Rock, Brooke M ^a   Tometsko, Mark E ^a   Patel, Sonal K ^a   Hamblett, Kevin J ^a   Fanslow, William C ^a   Rock, Dan A ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; ANTIBODY DRUG CONJUGATE; CD70 AB MCC DM1 ANTIBODY; CYTOTOXIC AGENT; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; CD70 ANTIGEN; DRUG;

786 0 CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CATABOLISM; CELL LINE; CELL METABOLISM; CHEMICAL BINDING; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; IN VITRO STUDY; LYSOSOME; PRIORITY JOURNAL; HUMAN; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ANTIGENS, CD70; CELL LINE, TUMOR; HUMANS; IMMUNOCONJUGATES; LYSOSOMES; PHARMACEUTICAL PREPARATIONS;

EID: 84940398405     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.064253     Document Type: Article

References (19)

1. Alley SC, Okeley NM, and Senter PD (2010) Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 14:529-537.
2. Amiri-Kordestani L., Blumenthal GM, Xu Q.C., Zhang L., Tang SW, Ha L, Weinberg WC, Chi B, Candau-Chacon R, and Hughes P, et al. (2014) FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res 20: 4436-4441.
3. Bowman EJ, Siebers A, and Altendorf K (1988) Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 85: 7972-7976.
4. de Claro R.A., McGinn K, Kwitkowski V., Bullock J, Khandelwal A, Habtemariam B., Ouyang Y, Saber H, Lee K., and Koti K, et al. (2012) U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 18:5845-5849.
5. Doronina SO, Mendelsohn BA, Bovee T.D., Cerveny CG, Alley SC, Meyer DL, Oflazoglu E, Toki B.E., Sanderson RJ, and Zabinski RF, et al. (2006) Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity. Bioconjug Chem 17:114-124.
6. Erickson HK and Lambert JM (2012) ADME of antibody-maytansinoid conjugates. AAPS J 14: 799-805.
7. Erickson HK, Park PU, Widdison W.C., Kovtun YV, Garrett LM, Hoffman K, Lutz R.J., Goldmacher VS, and Blättler WA (2006) Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 66:4426-4433.
8. Erickson HK, Widdison WC, Mayo M.F., Whiteman K., Audette C, Wilhelm SD, and Singh R (2010) Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem 21:84-92.
9. Erickson HK, Lewis Phillips GD, Leipold DD, Provenzano CA, Mai E, Johnson H.A., Gunter B., Audette CA, Gupta M, and Pinkas J, et al. (2012) The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther 11:1133-1142.
10. Fishkin N, Maloney EK, Chari R.V., and Singh R (2011) A novel pathway for maytansinoid release from thioether linked antibody-drug conjugates (ADCs) under oxidative conditions. Chem Commun (Camb) 47:10752-10754.
11. Gjoen T, Berg TO, and Berg T (1997) Lysosomes and endocytosis, in Subcellular Fractionation: A Practical Approach (Graham J, Rickwood D eds) pp 169-200, IRL Press Limited, Oxford, England.
12. Han TH and Zhao B (2014) Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates. Drug Metab Dispos 42:1914-1920.
13. Kovtun YV, Audette CA, Ye Y, Xie H., Ruberti MF, Phinney SJ, Leece BA, Chittenden T, Blättler WA, and Goldmacher VS (2006) Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen. Cancer Res 66:3214-3221.
14. Lambert JM and Chari RV (2014) Ado-trastuzumab Emtansine (T-DM1): an antibody-drug conjugate (ADC) for HER2-positive breast cancer. J Med Chem 57:6949-6964.
15. Lin K, Tibbitts J, and Shen BQ (2013) Pharmacokinetics and ADME characterizations of antibody-drug conjugates. Methods Mol Biol 1045:117-131.
16. Peddi PF and Hurvitz SA (2014) Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol 6:202-209.
17. Sassoon I and Blanc V (2013) Antibody-drug conjugate (ADC) clinical pipeline: a review. Methods Mol Biol 1045:1-27.
18. Shen BQ, Bumbaca D, Saad O., Yue Q, Pastuskovas CV, Khojasteh S.C., Tibbitts J., Kaur S, Wang B, and Chu YW, et al. (2012) Catabolic fate and pharmacokinetic characterization of trastu-zumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism. Curr Drug Metab 13:901-910.
19. Wakankar A, Chen Y, Gokarn Y., and Jacobson FS (2011) Analytical methods for physico-chemical characterization of antibody drug conjugates. MAbs 3:161-172.